In critically ill patients with blunted GH secretion, GHRP-2 maintained the ability to stimulate GH release, offering a potential strategy to combat the protein wasting and hormonal disruption of critical illness.
GHRP-2 works in critical illnessUnlike GHRH, GHRP-2 maintained its GH-releasing ability even when the GH axis was suppressed by critical illness
What the researchers found
GHRP-2 maintained GH-releasing efficacy in critically ill patients despite blunted responses to GHRH, suggesting a preserved alternative pathway for GH stimulation.
Why it matters
Muscle wasting in ICU patients significantly impacts recovery. If GHRP-2 can stimulate GH release when normal pathways are suppressed, it could help preserve muscle mass during critical illness.
How the study worked
Clinical study testing pituitary GH responses to GHRH, GHRP-2, and TRH in critically ill patients, comparing to expected normal responses.
What this study cannot tell us
Clinical study in critically ill patients — a heterogeneous population. Sample size and specific response magnitudes not detailed in abstract. Functional outcomes not assessed.
How to read the evidence
Moderate clinical evidence from a study in critically ill patients. Demonstrates preserved GHRP-2 responsiveness but lacks outcome data.
When this study was published
Published in 1996, this study highlighted GHRP-2's potential in critical care, an application area still under investigation.
The bigger picture
This study contributed to understanding how the GH axis is disrupted in critical illness and identified GHRP-2 as a potential intervention to combat ICU-related muscle wasting and metabolic dysfunction.
Questions still open
- Could GHRP-2 treatment reduce muscle wasting and improve outcomes in ICU patients?
- Should GH secretagogues be part of standard ICU endocrine management?
Common questions
Why is GH important in critical illness?
Why does GHRP-2 still work when GHRH doesn't?
Read the original research
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Clinical endocrinology, 45(3), 341-51
Citation
Van den Berghe, G; de Zegher, F; Bowers, C Y; Wouters, P; Muller, P; Soetens, F; Vlasselaers, D; Schetz, M; Verwaest, C; Lauwers, P; Bouillon, R. (1996). Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.. Clinical endocrinology, 45(3), 341-51.